Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00933985 · ClinicalTrials.gov registry record · Phase 1
Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT00933985: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00933985 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00933985, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of obatoclax mesylate when given together with vincristine sulfate, doxorubicin hydrochloride, and dexrazoxane hydrochloride in treating young patients with relapsed or refractory solid tumors, lymphoma, or leukemia. Obatoclax mesylate may stop the growth of cancer cells by blocking some of the proteins needed for cell growth and causing the cells to self-destruct. Drugs used in chemotherapy, such as vincristine sulfate, doxorubicin hydrochloride, and dexrazoxane hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving obatoclax mesylate together with combination chemotherapy may kill more cancer cells.
Interventions
- OTHER pharmacological study
- DRUG dexrazoxane hydrochloride
- DRUG doxorubicin hydrochloride
- DRUG liposomal vincristine sulfate
- DRUG obatoclax mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2009-06 |
| Est. Completion | 2013-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00933985
The ClinicalTrials.gov registry entry for NCT00933985 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which pharmacological study is the first listed.
NCT00933985 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00933985 about?
NCT00933985 is a clinical study titled "Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia". This phase I trial is studying the side effects and best dose of obatoclax mesylate when given together with vincristine sulfate, doxorubicin hydrochloride, and dexrazoxane hydrochloride in treating young patients with relapsed or refractory solid tumors, lymphoma, or leukemia. Obatoclax mesylate ma...
What is the current status of trial NCT00933985?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2009-06. Estimated completion is 2013-04.
What interventions are being tested in trial NCT00933985?
The interventions under investigation include: pharmacological study (OTHER), dexrazoxane hydrochloride (DRUG), doxorubicin hydrochloride (DRUG), liposomal vincristine sulfate (DRUG), obatoclax mesylate (DRUG).
Who is sponsoring clinical trial NCT00933985?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.